TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Na
Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

Cogent Biosciences announced that CEO Andrew Robbins will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. The company is developing precision therapies for genetically defined diseases, with bezuclastinib as its most advanced program for systemic mastocytosis and gastrointestinal stromal tumors. Recent positive trial results showed a 57-80% objective response rate in advanced systemic mastocytosis patients.

Insights
COGT   positive

The company is presenting at a major healthcare conference and has demonstrated positive clinical trial results with high objective response rates (57-80%) for its lead drug bezuclastinib in advanced systemic mastocytosis, indicating strong clinical progress and investor interest.